- The preliminary confidential target valuation is between $225M and $300M.
- The transaction would be executed simultaneously with Logiq’s pending Abri de-SPAC deal whereby the confidential target acquisition would become a wholly owned subsidiary of Logiq.
- Properly structured, post-transaction the combined entity is expected to apply for Nasdaq or NYSE up-listing and complete a significant capital raise
Infosys To Acquire Life Sciences Consulting And Technology Leader, BASE Life Science; Terms Not Disclosed
Infosys to Acquire Life Sciences Consulting and Technology Leader, BASE life science
Acquisition to deepen life sciences domain capabilities and strengthen footprint